Download PDF Return to Press Releases

Press Releases

Friday, October 20, 2000

Floyd E. Bloom, M.D.
Founding Chief Executive Officer
(858) 677-0466


LA JOLLA, CA – Neurome, Inc., a neuroscience company, announced today that it has raised $9 million in initial financing and, separately, established a commercial collaboration through a research partnership with Elan Pharmaceuticals, a division of Elan Corporation, plc ("Elan").

Investors in the $9 million financing include Digital Gene Technologies (DGT), Elan, and a group of prominent private biotech investors organized by the company. As part of the initial round of financing, DGT is providing a $1 million investment, together with in-kind services related to incubation and administrative support of Neurome in the DGT facility in La Jolla. Initial shareholders also include The Scripps Research Institute, Mount Sinai School of Medicine and company founders Dr. Floyd E. Bloom, Dr. John H. Morrison and Dr. Warren G. Young.

"The enthusiasm represented by this oversubscribed offering together with the immediate commercial partnership established with Elan, indicates strong support for the Neurome business model and provides the potential for significant revenues even while we are in an early phase of development," said Dr. Floyd E. Bloom, Neurome's chief executive officer. "The application of Neurome's advanced informatics tools to Elan's gold standard model system for brain pathology will offer further validation of Neurome's pioneering approach to brain research."

The research partnership with Elan has an initial term of 3 years and may generate up to $4 million in service revenue for Neurome, together with shared ownership of the diagnostic and therapeutic applications of the genes, circuits and mechanisms identified in the research.

The partnership will utilize Neurome's technologies to analyze a mouse model of Alzheimer's Disease with the goal of identifying and exploiting molecules and pathways relevant to diagnosis and treatment of the disease. The partnership will analyze Elan's proprietary mouse model of amyloid deposition in an attempt to answer a variety of scientific questions regarding amyloid deposition.

"Exploration of gene expression patterns in the mouse brain as they relate to cellular specialization and circuit characteristics is important to a better understanding of molecular and cellular pathogenesis of Alzheimer's Disease and other neurodegenerative disorders," commented Ivan Lieberburg, Ph.D., M.D., chief scientific & medical officer of Elan. "The combination of Neurome's remarkably sophisticated tools for integration and interpretation of biological data together with our mouse model will allow us to accelerate the research process and enable a valuable step in functional characterization of the genes of the brain."

Neurome's founders, Dr. Floyd E. Bloom and Dr. Warren G. Young, both of The Scripps Research Institute in La Jolla, California, and Dr. John H. Morrison, of Mount Sinai School of Medicine, New York City, New York, are leading computer-based neuroscientists and pioneers in the modern applications of neuroanatomy.

Dr. Bloom recently retired as the editor-in-chief of Science and is the chairman of the department of neuropharmacology at The Scripps Research Institute. Dr. Morrison is the Johnson Professor of Geriatrics and Adult Development at the Mount Sinai School of Medicine, where he is also director of the Kastor Neurobiology of Aging Laboratories and director of the Fishberg Research Center for Neurobiology. He will serve as Neurome's chief scientific officer. Dr. Young is the director of neuropharmacology computing at The Scripps Research Institute and the managing editor of Brain Research Interactive. He will serve as Neurome's chief technology officer.

The founders have jointly developed the "Neurome Technologies" which include: MiceSlice™ for standardized preparation of brain section tissues, the foundation material for development of standardized experimental protocols; NeuroZoom™ for precise, computer-aided extraction, analyses, and display of quantitative data from microscope images of brain; BrainArchive™, an electronic brain "atlas" for archiving, integration and comparison of brain structure and circuitry data; and, BrainPrint™ for automated comparison of quantitative, spatial, and volumetric data from mice, whether genetically-manipulated, wild-type, or control.

Neurome, Inc., develops standardized, quantitative databases that accurately depict and integrate gene expression patterns in the 3-dimensional context of the brain?s structures, circuits and cells, and deploys these databases in primary research directed toward the discovery and development of gene targets for enhancement of brain function and treatment of brain-based disease. Neurome performs contract brain research for pharmaceutical and biotechnology companies while at the same time pursuing its own in-house and collaborative research protocols. The data collected from these efforts will populate an evolving, comprehensive database available by subscription and useful on a broad level for analyses of mouse models of brain function and disease. In this regard, the application of the Neurome Technologies will provide rigorous, quantitative data that are optimally suited to the measurement of subtle cell-type specific shifts in gene expression, as well as progression and prevention of degenerative events affecting specific cell classes and brain regions.

For more information, please visit the Neurome, Inc., Web site at www.neurome.com or contact the Company at: Neurome, Inc., 11149 North Torrey Pines Road, La Jolla, CA 92037-1031. Telephone: (858) 677-0466; Fax: (858) 677-0458.

© 2005 Neurome, All Rights Reserved | Privacy Statement | Terms of Use | Forward Looking Statements